Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Evoke Pharma Inc Market Cap
From what 5 stock analysts predict, the share price for Evoke Pharma Inc (EVOK) might increase by 337.96% in the next year. This is based on a 12-month average estimation for EVOK. Price targets go from $18 to $18. The majority of stock analysts believe EVOK is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assignedEVOK 5 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Evoke Pharma Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on EVOK. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of EVOK.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Upgrade | Jun 22, 2020 |
H.C. Wainwright | Neutral | Downgrade | Mar 5, 2019 | |
Seaport Global | Buy | Initiates | Oct 6, 2017 | |
Laidlaw & Co. | Buy | Upgrade | Jan 30, 2017 | |
Rodman & Renshaw | Buy | $6 | Upgrade | Jan 5, 2017 |
Noble Financial | Hold | Downgrade | Jul 19, 2016 | |
Rodman & Renshaw | Neutral | $2 | Downgrade | Jul 18, 2016 |
Brean Capital | Hold | Downgrade | Jul 18, 2016 | |
Northland Securities | Outperform | Initiates | Mar 16, 2016 | |
Ascendiant Capital | Buy | $12 | Maintains | Mar 14, 2016 |
H.C. Wainwright | Buy | Initiates | Oct 1, 2015 | |
Brean Capital | Buy | Initiates | Aug 20, 2015 | |
MLV & Co. | Buy | Initiates | Nov 7, 2014 | |
Cantor Fitzgerald | Buy | $20 | Maintains | May 27, 2014 |
Laidlaw & Co. | Buy | Initiates | Apr 22, 2014 | |
Aegis Capital | Buy | Initiates | Nov 19, 2013 | |
Cantor Fitzgerald | Buy | Initiates | Nov 6, 2013 | |
Cantor Fitzgerald | Buy | Initiates | Nov 4, 2013 |
When did it IPO
2013
Staff Count
4
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—Specialty & Generic
CEO
Mr. Matthew J. D'Onofrio MBA
Market Cap
$3.4M
In 2023, EVOK generated $5.2M in revenue, which was a increase of 106.51% from the previous year. This can be seen as a signal that EVOK's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Wed, 18 Oct 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its real-world healthcare utilization data suggesting reduced healthcare costs for patients on GIMOTI versus patients on oral metoclopramide will be presented, as an oral plenary presentation, at the American College of Gastroenterology annual meeting taking place in Vancouver, BC, Canada from October 20-25, 2023.
Thu, 14 Sep 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that it has been granted a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application No. 17/366,829 pertaining to GIMOTI, the first and only FDA-approved nasal formulation of metoclopramide commercially available in the United States. When issued, the patent will cover the intranasal pharmaceutical composition of GIMOTI.
Thu, 10 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - 40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI compared to oral metoclopramide at DDW 2023; additional abstracts accepted at future medical conferences SOLANA BEACH, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced its financial results for the second quarter ended June 30, 2023, and recent corporate developments.
Mon, 07 Aug 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide
Tue, 25 Jul 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients”
Wed, 14 Jun 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Study between nasal and oral metoclopramide selected by Digestive Disease Week (DDW) 2023 faculty for plenary presentation Study between nasal and oral metoclopramide selected by Digestive Disease Week (DDW) 2023 faculty for plenary presentation
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
